CRISPR Therapeutics AG (NASDAQ:CRSP) COO Sells $50,819.16 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $50,819.16. Following the sale, the chief operating officer now directly owns 8,263 shares of the company’s stock, valued at $350,516.46. This represents a 12.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

CRISPR Therapeutics Trading Up 0.3 %

Shares of NASDAQ CRSP opened at $42.12 on Friday. The firm has a market cap of $3.61 billion, a PE ratio of -9.64 and a beta of 1.77. CRISPR Therapeutics AG has a 1-year low of $36.52 and a 1-year high of $75.91. The company has a fifty day moving average price of $43.06 and a 200 day moving average price of $45.58.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Equities research analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on CRSP. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Citigroup decreased their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a report on Tuesday, February 18th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a report on Thursday, February 13th. Finally, The Goldman Sachs Group decreased their price target on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $73.11.

Institutional Investors Weigh In On CRISPR Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRSP. Wood Tarver Financial Group LLC bought a new stake in CRISPR Therapeutics during the 4th quarter worth about $30,000. Ameriflex Group Inc. bought a new stake in CRISPR Therapeutics during the 4th quarter worth about $36,000. Highline Wealth Partners LLC bought a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $39,000. Western Pacific Wealth Management LP raised its holdings in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after purchasing an additional 500 shares during the period. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of CRISPR Therapeutics in the 3rd quarter valued at about $40,000. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.